Sutro Biopharma, Inc. (NASDAQ:STRO) Just Reported And Analysts Have Been Lifting Their Price Targets
Sutro Biopharma (NASDAQ:STRO) reported quarterly revenue of $9.8m, 11% below analyst expectations, and a statutory loss per share of $2.33, 6.2% worse than forecast. For 2026, 12 analysts project revenue of $44.4m and losses of $8.73 per share. The average price target fell 5.4% to $50.33, with targets ranging $34 to $61.
How this was made
The 30-second read
Why it matters
STRO faced a revenue miss and slightly worse-than-expected statutory loss per share, while analysts largely left 2026 forecasts unchanged but reduced the average price target.
Market read
Traders may treat this as a sentiment/valuation adjustment rather than a fundamental reset because next-year revenue and loss forecasts were not changed.
What to watch
The article does not provide details on pipeline progress, cash burn, or guidance drivers; those could dominate the stock’s next move versus the analyst target range.
Background
The piece reviews post-earnings consensus for Sutro Biopharma after last week’s quarterly results.
Ticker impact
STRO’s quarterly results missed expectations, with 2026 consensus revenue held near $44.4m while the average price target fell 5.4% to $50.33.
Near-term downside bias from sentiment/valuation, with limited fundamental change because 2026 estimates were reconfirmed.
The article cites a revenue miss and a lower average price target, but also states analysts did not change next-year revenue or loss forecasts, limiting incremental fundamental impact.
Market effects
Signals continued caution on small-cap biotech profitability trajectories when quarterly results miss, even if longer-dated estimates remain stable.
No specific regional spillover described.
No global macro or cross-border catalyst mentioned.
Counterpoint
If 2026 revenue and loss forecasts were reconfirmed, the target cut may reflect sentiment rather than deteriorating fundamentals, leaving room for mean reversion if subsequent quarters stabilize.
Key entities
- companySutro Biopharma, Inc.
NASDAQ-listed biotech whose quarterly results missed expectations and whose 2026 consensus forecasts were largely reconfirmed, alongside a lower average analyst price target.
